P140 peptidefor lupus The field of immunotherapy is continuously evolving, seeking novel and effective ways to modulate the immune system for therapeutic benefitSpliceosomal Peptide P140 for Immunotherapy of SLE. Among the emerging candidates, peptide P140 has garnered significant attention for its unique immunomodulatory properties, particularly in the context of autoimmune diseases like systemic lupus erythematosus (SLE). This spliceosomal peptide is derived from the human U1-70K protein and has demonstrated a remarkable ability to restore immune homeostasis by targeting hyper-activated autoreactive immune cells.
Understanding the Science Behind Peptide P140
At its core, peptide P140 is a synthetic peptide sequence, specifically a 21-mer fragment (131-151) of the U1-70K protein, which is phosphorylated at the serine 140 position. This modification is crucial to its function.HSC70 blockade by the therapeutic peptide P140 affects ... Research indicates that P140 acts by binding to the HSPA8/HSC70 chaperone protein, a protein that plays a role in cellular stress responses and protein folding. By blocking the activity of HSC70, peptide P140 appears to influence the behavior of autoreactive T and B cells.
Studies have shown that P140 peptide can lead to the depletion of hyper-activated autoreactive T and B cells while simultaneously restoring normal immune homeostasis. This mechanism is key to its potential efficacy in autoimmune conditions where the immune system mistakenly attacks the body's own tissuesLupus Regulator Peptide P140 Represses B Cell .... Furthermore, P140 has been observed to increase peripheral blood lymphocyte apoptosis and decrease autoepitope recognition by T cells in preclinical models. This suggests a targeted approach to calming down an overactive and misdirected immune response.
Clinical Investigations and Therapeutic Applications
The therapeutic potential of peptide P140, also known by its investigational drug name Lupuzor (or Forigerimod, IPP 201101, CEP 33457, Rigerimod, SyB 1001), has been explored in clinical trials, primarily for systemic lupus erythematosus. Early phase clinical trials, including a randomized, double-blind, placebo-controlled phase IIb trial, have investigated the safety, tolerability, and efficacy of this peptide. While a longer treatment period might be necessary to see the full spectrum of responders, the results have been encouraging.
One of the significant findings is that P140 down-regulates HLA class II overexpression in human lupus B cells and hampers their function. This is a critical observation, as HLA class II molecules are involved in presenting antigens to T cells, a process that can perpetuate autoimmune responses. By modulating this, peptide P140 offers a novel therapeutic strategy distinct from existing treatments for lupus.
Beyond SLE, preliminary research has also explored the effects of peptide P140 in other inflammatory conditions.Spliceosomal peptide P140 for immunotherapy of systemic ... For instance, studies have investigated its impact on inflammatory responses in models of gout, suggesting a broader potential for this immunomodulating peptide. The safety profile of P140 has also been noted, with reports indicating its safety in clinical trials involving hundreds of autoimmune patients.
The Future of Peptide P140
The ongoing research into peptide P140 highlights its promise as a novel therapeutic agent. Its ability to target specific components of the immune system without causing broad immunosuppression is a significant advantage. As studies continue, particularly regarding Lupuzor FDA approval and Lupuzor Phase 3 results, we may see peptide P140 become a valuable tool in the management of autoimmune diseases and potentially other conditions characterized by immune dysregulation.P140is apeptidefrom the small nuclear ribonucleoprotein U1-70K, phosphorylated at the Ser140 position.P140binds to the HSPA8/HSC70 chaperone protein, ... The exploration of P140 peptide for sale and P140 peptide for sale online reflects the growing interest in accessing this promising compound for further research and potential therapeutic use.
The development of peptide P140 represents a significant advancement in the understanding and treatment of complex immune-mediated disordersP140 Peptide Leads to Clearance of Autoreactive .... Its mechanism of action, targeting autoreactive cells and restoring immune balance, offers a new paradigm for immunotherapy.
Join the newsletter to receive news, updates, new products and freebies in your inbox.